APOLIPOPROTEIN A1 AND APOLIPOPROTEIN B LEVELS, THEIR ASSOCIATIONS WITH ESTIMATED GLOMERULAR FILTRATION RATE AND SELECTED CHARACTERISTICS IN NON-DIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE AT HANOI KIDNEY HOSPITAL IN 2026
Main Article Content
Abstract
Background: Lipoprotein metabolism abnormalities are common in patients with chronic kidney disease (CKD) and are clinically relevant given the increased cardiovascular risk in this population. Apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B), and the Apo B/Apo A1 ratio may provide additional information on lipoprotein abnormalities beyond conventional lipid parameters. However, data on these parameters and their associations with kidney function in non-dialysis patients with CKD in Vietnam remain limited.
Objectives: To determine the concentrations of apolipoprotein A1, apolipoprotein B, and the Apo B/Apo A1 ratio, and to evaluate their associations with estimated glomerular filtration rate (eGFR) and selected clinical and laboratory characteristics in non-dialysis patients with CKD.
Methods: A cross-sectional study was conducted in 236 participants, including 140 non-dialysis patients with CKD recruited at Hanoi Kidney Hospital and 96 healthy blood donors recruited at Military Central Hospital 108 and Duc Giang General Hospital, from January 1 to August 31, 2026.
Results: Among the 140 non-dialysis patients with CKD, the median Apo A1 and Apo B concentrations were 1.405 g/L and 0.840 g/L, respectively, and the median Apo B/Apo A1 ratio was 0.627; all three measures were significantly higher than those in the control group (p<0.05). Apo A1 was significantly lower in patients with eGFR <60 mL/min/1.73 m² than in those with eGFR ≥60 mL/min/1.73 m² (1.390 vs. 1.510 g/L; p=0.039), whereas no significant differences were observed for Apo B or the Apo B/Apo A1 ratio. No significant correlations were observed between continuous eGFR and Apo A1, Apo B, or the Apo B/Apo A1 ratio. Apo A1 was positively correlated with HDL-C, total cholesterol, and LDL-C; Apo B was positively correlated with total cholesterol, triglycerides, and LDL-C; and the Apo B/Apo A1 ratio was positively correlated with BMI, total cholesterol, triglycerides, and LDL-C and negatively correlated with HDL-C (p<0.05).
Conclusion: Apo A1, Apo B, and the Apo B/Apo A1 ratio were significantly higher in non-dialysis patients with CKD than in healthy individuals. Apo A1 was correlated with several lipid parameters, whereas Apo B and the Apo B/Apo A1 ratio were correlated with several lipid parameters and BMI. However, no significant correlations were observed between continuous eGFR and Apo A1, Apo B, or the Apo B/Apo A1 ratio.
Keywords
Apolipoprotein A1, apolipoprotein B, Apo B/Apo A1 ratio, chronic kidney disease, estimated glomerular filtration rate, lipid profile
Article Details
References
2. Goek ON, Köttgen A, Hoogeveen RC, Ballantyne CM, Coresh J, Astor BC. Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrol Dial Transplant. 2012;27(7):2839-2847. doi:10.1093/ndt/gfr795
3. Lecamwasam A, Mansell T, Ekinci EI, Saffery R, Dwyer KM. Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk. Front Nutr. 2022;9:821209. doi:10.3389/fnut.2022.821209
4. Mehta A, Shapiro MD. Apolipoproteins in vascular biology and atherosclerotic disease. Nat Rev Cardiol. 2022;19(3):168-179. doi:10.1038/s41569-021-00613-5
5. Xu Y, Liu B, Lin L, et al. The association of apolipoprotein B with chronic kidney disease in the Chinese population. Front Endocrinol. 2023;14:1083614. doi:10.3389/fendo.2023.1083614
6. Mazidi M, Webb RJ, Lip GYH, Kengne AP, Banach M, Davies IG. Discordance between LDL-C and Apolipoprotein B Levels and Its Association with Renal Dysfunction: Insights from a Population-Based Study. J Clin Med. 2022;11(2):313. doi:10.3390/jcm11020313
7. Lamprea-Montealegre JA, Sharrett AR, Matsushita K, Selvin E, Szklo M, Astor BC. Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: The ARIC Study. Atherosclerosis. 2014;234(1):42-46. doi:10.1016/j.atherosclerosis.2014.02.006
8. Dounousi E, Tellis C, Pavlakou P, Duni A, Liakopoulos V, Mark PB, et al. Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients. Oxidative Medicine and Cellular Longevity. 2021:6677012. doi: 10.1155/2021/6677012.
9. Kwon S, Kim DK, Oh KH, et al. Apolipoprotein B is a risk factor for end-stage renal disease. Clin Kidney J. 2020;14(2):617-623. doi:10.1093/ckj/sfz186
10. Welsh C, Celis-Morales CA, Brown R, Mackay DF, Lewsey J, Mark PB, et al. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation. 2019. Aug 13;140(7):542-552. doi: 10.1161/CIRCULATIONAHA.119.041149
11. Sniderman AD, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G, Pencina MJ. Discordance among Apo B, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur heart J. 2024. Jul 12;45(27):2410-2418. doi: 10.1093/eurheartj/ehae258.